CompletedPhase 1NCT00003962
Interleukin-2 Following Bone Marrow Transplantation in Treating Patients With Hematologic Cancer
Studying Acute biphenotypic leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Principal Investigator
- Paul V. O'Donnell, MD, PhDFred Hutchinson Cancer Center
- Intervention
- aldesleukin(biological)
- Eligibility
- 65 years · All sexes
- Timeline
- 1998 – 2000
Study locations (1)
- Johns Hopkins Oncology Center, Baltimore, Maryland, United States
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00003962 on ClinicalTrials.govOther trials for Acute biphenotypic leukemia
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONPHASE2NCT07517510HVA in the Treatment of Mixed-Phenotype Acute Leukemia(MPAL).Guangdong Second Provincial General Hospital
- RECRUITINGPHASE1, PHASE2NCT07356154A Study of Revumenib and Mezigdomide in People With LeukemiaMemorial Sloan Kettering Cancer Center
- RECRUITINGNCT07537738Leukemia Stem Cell-based Assay to Predict Relapse and Survival in Patients With Acute Myeloid LeukemiaPeking University People's Hospital
- RECRUITINGPHASE1, PHASE2NCT05589896A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic MalignanciesOssium Health, Inc.
- RECRUITINGNANCT05794880MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG DosingMedical College of Wisconsin
- ACTIVE NOT RECRUITINGPHASE2NCT03399773Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplastic SyndromesFred Hutchinson Cancer Center
- RECRUITINGPHASE1, PHASE2NCT04797767Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid NeoplasmsUniversity of Washington
- ACTIVE NOT RECRUITINGPHASE2NCT04975919Venetoclax in Combination With Decitabine and Cedazuridine for the Treatment of Relapsed or Refractory Acute Myeloid LeukemiaM.D. Anderson Cancer Center